Rex Health Ventures
VC Fund
Raleigh, United States
Rex Health Ventures is a VC fund in Raleigh focused on Health Care and Medical. Rex Health Ventures (RHV) supports the discovery and development of new treatments, tools, products and services that foster innovation and positively impacts the provision of healthcare. They invest in and partner with companies and entrepreneurs to help bring their products and services into the healthcare marketplace.
- Total investments:
- 28
- Last investment:
- Lead investor:
- 18%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Rex Health Ventures invests in
Stages Rex Health Ventures invests in
Countries Rex Health Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anita Watkins
|
|||
Ray Jang
|
|||
3 more contacts available
Investment Focus
Industry
- Health Care 15 (54%)
- Medical 9 (32%)
- Medical Device 9 (32%)
- Biotechnology 6 (21%)
- Biopharma 4 (14%)
Stage
- Series B 10 (36%)
- Series A 5 (18%)
- Funding Round 5 (18%)
- Series C 4 (14%)
- Venture - Series Unknown 3 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Anita Watkins
Managing Director
|
Managing Director | Total investments: 3 | Find email | |
|
Ray Jang
Senior Associate
|
Senior Associate | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
410 Medical
|
410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina. | $12M / Venture - Series Unknown / Jul 14, 2026 | |
Reprieve Cardiovascular
|
Reprieve Cardiovascular is a pioneering medical device company focused on innovative fluid management technologies for congestive heart failure. The company's Reprieve technology is being investigated as an innovative fluid management treatment. Providing clinicians with the ability to precisely control a patient’s fluid volume may both enableimproved cardiac care, as well as, be instrumental in the decongestion of acutely decompensated heart failure patients (ADHF). Reprieve Cardiovascular, Inc. and RenalGuard Solutions, Inc. are subsidiaries of parent company CardioRenal Systems, Inc. | $61M / Series B / Aug 13, 2025 | |
Carta Healthcare
|
Carta empowers hospitals to personalize the delivery of care to the individual needs of each patient. The approach Carta Healthcare is advocating and enabling is to: find past patients similar to the current one being treated; quantify what exactly happened to them during their journey through the hospital (this is where our model comes in) and;use machine learning to project what the particular patient in question will need, and what the patient can expect their experience to be in the hospital. Carta was founded in 2017 and is based in Palo Alto, California, United States. | $18.3M / Series B / May 07, 2025 | |
|
410 Medical
|
410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina. | $14M / Series B / Mar 17, 2025 | |
G.I. Windows
|
G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The company is creating a new category in healthcare designed to create less invasive surgery and reducehealthcare costs.G.I. Windows is committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system. It was founded in 2012 and is headquartered in West Bridgewater, Massachusetts, United States. | $37M / Nov 20, 2024 | |
|
G.I. Windows
|
G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The company is creating a new category in healthcare designed to create less invasive surgery and reducehealthcare costs.G.I. Windows is committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system. It was founded in 2012 and is headquartered in West Bridgewater, Massachusetts, United States. | $37M / Series B / Nov 20, 2024 | |
Synaptrix
|
Synaptrix is committed to offering free of drugs, lasting alternatives for postoperative pain treatment using NOVABLOC. | $10M / Series A / Nov 15, 2024 | |
Arrivo BioVentures LLC
|
Our expertise is drug development. Whether we are developing a reformulated product, a new chemical entity, or a biologic, the team at Arrivo BioVentures has expertise in identifying regulatory strategies to expedite the path to approval and the efficient implementation of the clinical programs themselves. We coordinate with the FDA (and otherregulatory bodies) early and often to gain agreement on the development programs for our products, minimizing surprises and speeding implementation. | $45.3M / Series B / Nov 29, 2023 | |
Censinet
|
Censinet fundamentally redefines the way vendor risk is managed in healthcare. Unlike other solutions, Censinet not only streamlines and simplifies workflows, but also standardizes risk questions with breadth and accuracy of risk ratings. Only Censinet was developed exclusively by and for healthcare providers, which makes Censinet the first andonly Collaborative Cloud Platform for Vendor Risk Management. | $9M / Venture - Series Unknown / Jan 11, 2023 | |
Vergent Bioscience
|
While the complete removal of residual cancer at the tumor margins during the surgical resection of solid tumors is closely linked with improved cure rates, it is often difficult for even experienced surgeons to distinguish cancerous tissue from normal tissue. Visual differentiation is needed at the cellular level. Vergent'smolecularly-targeted imaging molecule, VGT-309, binds to enzymes that are overexpressed in tumor tissue, activating a brightly fluorescing dye. This proprietary molecule can identify and bind to multiple cancers including lung, breast, ovarian, colorectal, and brain, among others. When injected prior to surgery, VGT-309 “lights up” cancerous tissue and gives the surgeon a clear visual guide for the removal procedure.Vergent’s approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic surgery procedures, while uniquely retaining the pricing flexibility required for success in a value-based healthcare system. | $21.5M / Series B / Oct 04, 2022 | |
| See all 28 investments → | |||
Co-Investors
Orlando Health Ventures
7 deals together
Easton Capital
4 deals together
Kaiser Permanente Ventures
4 deals together
LionBird
4 deals together
New Leaf Venture Partners
4 deals together
DUMAC
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Rex Health Ventures invest in?
Rex Health Ventures invests primarily in Health Care, Medical and Medical Device startups, most often at Series B and Series A stage. Most of the 28 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Rex Health Ventures?
Public channels for Rex Health Ventures include X (Twitter), the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Rex Health Ventures?
The team at Rex Health Ventures includes Anita Watkins (Managing Director) and Ray Jang (Senior Associate). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
